Shares of Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.68 and traded as high as $1.83. Advaxis shares last traded at $1.79, with a volume of 5,385 shares.
Analyst Upgrades and Downgrades
Separately, StockNews.com initiated coverage on Advaxis in a research report on Monday. They issued a "sell" rating on the stock.
Get Advaxis alerts:Advaxis Stock Performance
The firm has a market capitalization of $3.25 million, a price-to-earnings ratio of -0.20 and a beta of 2.44. The company has a 50 day moving average price of $1.73 and a two-hundred day moving average price of $1.68.
About Advaxis
(Get Rating)
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Featured Articles
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.